Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 6, 2024
Product Development
Tale of two WRN inhibitors: a covalent and a non-covalent molecule enter the clinic
As the first two programs targeting the helicase WRN enter the clinic for MSI+ cancers, they set up a comparison of different inhibitory mechanisms
BioCentury | Oct 5, 2023
Regulation
Oct. 4 Quick Takes: FDA’s ODAC backs US WorldMeds’ eflornithine for neuroblastoma
Plus: ClavystBio launches space for start-ups in Singapore and updates from Novavax, Iambic, Sandoz, Shorla and more
BioCentury | Apr 29, 2023
Regulation
Lynparza panel vote advances FDA’s precision oncology agenda
ODAC votes for a biomarker-restricted label for Lynparza in prostate cancer
BioCentury | Apr 14, 2022
Product Development
DDR combos on the horizon at AACR22
The first clinical data for a PARP1-selective inhibitor and deeper profiles of ATR-targeting agents suggest combinations will shape the field’s next act
BioCentury | Nov 19, 2021
Discovery & Translation
An improved method for TIL expansion and screening; plus Metagenomi, Sitryx and more
BioCentury’s roundup of translational news
BioCentury | Nov 13, 2021
Discovery & Translation
Repare identifies new BRCA synthetic lethal relationship; plus Immune-Onc, Acuitas and more
BioCentury’s roundup of translational news
BioCentury | Oct 21, 2021
Management Tracks
Dana-Farber’s David Livingston dies at 80
Plus: Alzheimer's Association, Aerie, Elevation, BioPorto, Opus and more
BioCentury | Apr 30, 2021
Distillery Therapeutics
Blocking NLRP3 deubiquitination for inflammasome-associated disease
DISEASE CATEGORY: Autoimmune; hepatic; infectious; inflammation
INDICATION: Multiple sclerosis (MS); liver disease; sepsis; inflammation Inhibiting the BRCC3-containing isopeptidase complex
INDICATION: Multiple sclerosis (MS); liver disease; sepsis; inflammation Inhibiting the BRCC3-containing isopeptidase complex
BioCentury | Nov 18, 2020
Emerging Company Profile
InterVenn: liquid biopsy diagnostics based on glycoproteins
InterVenn builds on research by scientific founders Bertozzi, Lebrillo to develop glycoproteomic cancer diagnostics
Items per page:
1 - 10 of 343